Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Active, not recruiting · NCT02749903 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | Digestive System Diseases, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, adenocarcinoma, carcinoma, digestive system disorder, epithelial neoplasm, hypertrophic pyloric stenosis, mouth disorder, neoplasm, pyloric stenosis, salivary duct carcinoma, salivary gland basal cell adenocarcinoma, salivary gland cancer, salivary gland disorder, stomach disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT02749903 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 79 |
| Astellas Pharma US, Inc. | 8 |
| National Cancer Institute (NCI) | 3015 |
287 results · Page 1 of 12
Research sites
Swipe the table sideways for more columns.